Cedilla Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cedilla Therapeutics's estimated annual revenue is currently $697.5k per year.
- Cedilla Therapeutics's estimated revenue per employee is $77,500
- Cedilla Therapeutics's total funding is $138.8M.
Employee Data
- Cedilla Therapeutics has 9 Employees.
- Cedilla Therapeutics grew their employee count by -71% last year.
Cedilla Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Business Officer & Head Finance | Reveal Email/Phone |
2 | Senior Scientist | Reveal Email/Phone |
3 | Scientist | Reveal Email/Phone |
Cedilla Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Cedilla Therapeutics?
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit www.cedillatx.com.
keywords:N/A
$138.8M
Total Funding
9
Number of Employees
$697.5k
Revenue (est)
-71%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cedilla Therapeutics News
Three of the earliest employees at G1 Therapeutics want to repeat the blueprint ... CDK2: Monte Rosa, Cedilla Therapeutics and Nuvation Bio.
Workit Health raised $90M; Cedilla Therapeutics secured $25; Selfbook landed $25M Thrasio: Thrasio is a Boston-based outfit that acquires and aggregates third-party merchants selling on Amazon and other marketplace platforms. Thrasio has raised $1 billion in Series D funding at a $10 billion va ...
Cedilla Therapeutics, a Cambridge, Mass.-based biotechnology company focused on precision oncology, raised $25m in an expansion of its Series B financing, bringing the total amount raised to $82.6m. The Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, ...
Cedilla Therapeutics, a Cambridge, MA-based biotechnology company, raised $56.2m in Series A funding. Third Rock Ventures made the investment. Launched in 2018 by Third Rock Ventures and by Alexandra Glucksmann, Ph.D., president and chief executive officer, by Brian Jones, Ph.D., chief scienti ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | -10% | N/A |
#4 | $0.7M | 9 | -25% | N/A |
#5 | $1.4M | 9 | -25% | N/A |